VolitionRx Limited announced the signing of a global supply agreement with a market leader in pet healthcare. Through Volition's supply agreement, the Company is engaged as a worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health. There are approximately 84 million pet dogs in the United States and just under 50% of dogs will have at least one veterinary care visit per annum which Volition believes will provide an incredible opportunity to screen those senior dogs (over 7 years) and breeds at risk of cancer from 4 years and upwards.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.746 USD | +3.10% | -7.24% | +3.50% |
14/05 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
13/05 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.50% | 59.93M | |
-31.72% | 9.87B | |
-16.78% | 2.75B | |
-17.50% | 2.13B | |
-24.65% | 1.65B | |
+66.49% | 1.47B | |
+32.67% | 811M | |
-5.02% | 733M | |
-30.10% | 510M | |
+0.20% | 300M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- VolitionRx Limited Signs Global Supply Agreement for Nu.Q® Vet Cancer Test